Adial Pharmaceuticals Secures Patent Protection for AD04 Alcohol Use Disorder Therapy Through 2045
核心洞察
Adial Pharmaceuticals announced the publication of an international PCT patent application for AD04, its lead genetically targeted serotonin-3 receptor (搜索) antagonist for treating Alcohol Use Disorder (搜索) in heavy drinking patients.
The patent, filed in July 2024 and expected to be granted, will protect Adial's core assets through at least 2045, significantly extending the company's intellectual property exclusivity.
AD04 targets heavy drinking patients defined as consuming fewer than 10 drinks per drinking day and is being developed for a new Phase 3 clinical trial program using the company's proprietary diagnostic genetic test.
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) announced on January 14, 2026, the publication of its international PCT patent application for AD04, the company's lead investigational therapy for Alcohol Use Disorder (搜索) (AUD). The patent application, originally filed in July 2024, is expected to extend intellectual property protection for Adial's core assets through at least 2045.
Genetically Targeted Approach to Alcohol Use Disorder
AD04 represents a genetically targeted serotonin-3 receptor (搜索) antagonist specifically designed for treating AUD in heavy drinking patients, defined as those consuming fewer than 10 drinks per drinking day. The therapy utilizes Adial's proprietary diagnostic genetic test to identify patients with specific target genotypes who may benefit most from treatment.
"As we continue to advance the AD04 program with planning for the next phase of our clinical program, the new patent application and its expected approval will extend protection of the core assets of Adial out to at least 2045," said Cary Claiborne, President and Chief Executive Officer of Adial Pharmaceuticals.
Clinical Development and Previous Results
Adial is currently planning to conduct a new Phase 3 clinical trial program for AUD treatment in subjects with certain target genotypes identified through the company's genetic testing platform. The previous ONWARD study demonstrated promising results, showing reduced drinking in heavy drinking patients with no overt safety or tolerability concerns.
The clinical-stage biopharmaceutical company focuses specifically on developing treatments for addictions and related disorders, with AD04 serving as its flagship therapeutic candidate.
Expanded Therapeutic Potential
Beyond alcohol use disorder (搜索), AD04 is believed to have potential applications in treating other addictive disorders, including Opioid Use Disorder (搜索), gambling addiction, and obesity. This broader therapeutic scope could significantly expand the commercial opportunity for the serotonin-3 receptor (搜索) antagonist platform.
Intellectual Property Strategy
The patent application resulted from an extensive examination of data and information conducted after Adial hired new patent counsel to strengthen and leverage the company's intellectual property portfolio. Claiborne noted that this strategic move was designed to "bolster and leverage Adial's intellectual property portfolio."
The extended patent protection through 2045 provides Adial with substantial market exclusivity for its core therapeutic assets, potentially offering significant competitive advantages as the company advances through clinical development and toward potential commercialization.